Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature.J Crohns Colitis. 2019 Oct 28; 13(11):1470-1473.JC
Abstract
Use of ustekinumab in Crohn's disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn's disease, who developed an anaplastic large cell T cell lymphoma during treatment with ustekinumab.
Links
MeSH
Pub Type(s)
Case Reports
Journal Article
Review
Language
eng
PubMed ID
31116402
Citation
Smeets, Fabiënne G M., et al. "Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease On Long-standing Immunosuppressive Medication During Ustekinumab Treatment: a Case Report and Review of the Literature." Journal of Crohn's & Colitis, vol. 13, no. 11, 2019, pp. 1470-1473.
Smeets FGM, Liedorp PR, van der Poel M, et al. Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. J Crohns Colitis. 2019;13(11):1470-1473.
Smeets, F. G. M., Liedorp, P. R., van der Poel, M., Miclea, R. L., Masclee, A. A. M., & Pierik, M. (2019). Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature. Journal of Crohn's & Colitis, 13(11), 1470-1473. https://doi.org/10.1093/ecco-jcc/jjz084
Smeets FGM, et al. Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease On Long-standing Immunosuppressive Medication During Ustekinumab Treatment: a Case Report and Review of the Literature. J Crohns Colitis. 2019 Oct 28;13(11):1470-1473. PubMed PMID: 31116402.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Anaplastic Large Cell T Cell Lymphoma in a Patient With Severe Therapy-refractory Crohn's Disease on Long-standing Immunosuppressive Medication During Ustekinumab Treatment: A Case Report and Review of the Literature.
AU - Smeets,Fabiënne G M,
AU - Liedorp,Paulien R,
AU - van der Poel,Marjolein,
AU - Miclea,Razvan L,
AU - Masclee,Ad A M,
AU - Pierik,Marieke,
PY - 2019/5/23/pubmed
PY - 2020/3/31/medline
PY - 2019/5/23/entrez
KW - Crohn’s disease
KW - Ustekinumab
KW - lymphoma
SP - 1470
EP - 1473
JF - Journal of Crohn's & colitis
JO - J Crohns Colitis
VL - 13
IS - 11
N2 - Use of ustekinumab in Crohn's disease was approved in 2016, and consequently data regarding its real-world safety are still limited. We here present a 29-year-old woman with severe therapy-refractory Crohn's disease, who developed an anaplastic large cell T cell lymphoma during treatment with ustekinumab.
SN - 1876-4479
UR - https://www.unboundmedicine.com/medline/citation/31116402/Anaplastic_Large_Cell_T_Cell_Lymphoma_in_a_Patient_With_Severe_Therapy_refractory_Crohn's_Disease_on_Long_standing_Immunosuppressive_Medication_During_Ustekinumab_Treatment:_A_Case_Report_and_Review_of_the_Literature_
DB - PRIME
DP - Unbound Medicine
ER -